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Abstract: Implementation of the Quality by Design (QbD) approach in pharmaceutical 
development has compelled researchers in the pharmaceutical industry to employ Design 
of Experiments (DoE) as a statistical tool, in product development. Among all DoE 
techniques, response surface methodology (RSM) is the one most frequently used. Progress 
of computer science has had an impact on pharmaceutical development as well. 
Simultaneous with the implementation of statistical methods, machine learning tools took 
an important place in drug formulation. Twenty years ago, the first papers describing 
application of artificial neural networks in optimization of modified release products 
appeared. Since then, a lot of work has been done towards implementation of new 
techniques, especially Artificial Neural Networks (ANN) in modeling of production, drug 
release and drug stability of modified release solid dosage forms. The aim of this paper is 
to review artificial neural networks in evaluation and optimization of modified release solid 
dosage forms. 
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1. Introduction 
The recent regulations from federal agencies, to apply the Quality by Design approach in 
pharmaceutical development, have compelled researchers in pharmaceutical industry to employ design 
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of experiments (DoE) during product development. The benefits of DoE in product and process 
optimization are evident; it is the most convenient way to link the drug and excipient attributes and the 
process parameters to the Critical Quality Attributes (CQAs). Furthermore, its usage is necessary in 
defining and controlling Design Space [1]. Design Space is the multidimensional combination and 
interaction of input variables (e.g., material attributes) and process parameters that have been 
demonstrated to provide assurance of quality. 
In the 1980s the use of DoE, especially factorial design, was generalized in the development of 
solid dosage forms. Statistical tools allowed the determination of critical process parameters of 
complex processes, as well as improvement and optimization of formulations [2]. 
Among diversity of DoE techniques, Response Surface Methodology (RSM) is the most frequently 
used optimization technique [2], which allows using polynomial equation(s) to link monitored 
responses to inputs:  
y = f (x1, x2, …, xq) + e (1)
where y is response and x1, x2, …, xq are inputs.  
This equation presents a mathematical description of a relationship between inputs and output. The 
advantage of this empirical model is that one can easily, without knowing true (i.e., mechanistic) link 
between inputs and outputs, describe their relationship. However, since the relationship between inputs 
and outputs is often more complicated, the observed model sometimes results in poor estimation of 
optimal conditions [2]. Drawbacks of this statistical approach were overcome in the 1990s, when, with 
the development of computer science, researchers started to apply machine learning. 
Machine learning is a branch of artificial intelligence. It is a scientific discipline involved in design 
and development of algorithms that allow computers to evolve behaviors based on empirical data. 
Machines “learn” to automatically recognize complex patterns, to distinguish between exemplars 
based on their different patterns, and to make intelligent decisions. There are several machine learning 
disciplines, such as: decision tree learning, association rule learning, artificial neural networks, genetic 
programming, support vector machines, clustering, Bayesian networks, etc. [3]. Among these, artificial 
neural networks are the most frequently applied in pharmaceutical development [4].  
In order to define and control the design space, the most effective approach is to complement DoE 
with some of the more advanced machine learning techniques, such as ANNs. DoE allows easy set-up 
of levels and boundaries of the materials attributes and processing parameters that are influencing 
CQAs. But, the linkage between the input(s) and the output(s) often requires non-linear modeling 
techniques that are advanced in comparison to DoE approaches. DoE models are polynomial, whereas 
machine learning offers a diverse variety of classification and modeling techniques.  
2. Artificial Neural Networks 
Artificial neural networks (ANNs) are computer programs, which recognize patterns in a given 
collection of data and produce model for that data. It emulates brain in two respects: (1) knowledge is 
acquired by the network through a learning process (trial and error); and (2) interneuron connection 
strengths (i.e., synaptic weights), are used to store the knowledge [4,5]. 
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Because neuroscience is still full of questions and because there are many levels of abstraction and 
many ways to take inspiration from the brain, there is no single definition of what an artificial network 
is. Most would agree that it involves a network of single processing elements which can exhibit 
complex behavior determined by the connections between the processing elements and element 
parameters [4,5]. 
Since design of artificial networks has been inspired by the structure of the human brain, it is 
pertinent to review/compare the function of biological neural network versus artificial ones. 
The fundamental processing unit of the human brain is the neuron (Figure 1). The neurons are 
linked together by dendrites, which serve to deliver messages to the neuron. Each neuron has an output 
channel, known as an axon by which signals can be transmitted unchanged or altered by synapses.  
Figure 1. Schematic representation of biological neuron. 
 
In the artificial neural network the logic processing unit is the neuron (“neurode”, “processing 
element” (PE) or “unit”), which takes one or more inputs and produces an output. At each neuron 
every input has an associate weight (w1,...wn, Figure 2) that defines relative importance of each input 
connected to the neuron. Set of inputs are multiplied with sets of weights; those set of inputs are 
summed together, and fed into a function to produce an output (yk, Figure 2). 
Figure 2. Schematic representation of artificial neuron. 
 
Every ANN is defined with architecture (number of layers, in each layer number of neurons, way in 
which neurons are connected, inter-neuron connections) and learning algorithm [4]. 
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2.1. What Happens between Neurons in a Network? 
In Figure 3, the simplest ANN is presented, which is a feed-forward neural network. A set of system 
inputs are transferred to the other neurons through synapses. The synapses store parameters called 
“weights” that manipulate the data in the calculations. Therefore, the set of inputs are multiplied with a 
set of adjustable weights. Weights are fed into the set of processing elements which then produce the 
set of outputs. The set of outputs are fed in another layer of weights, following another layer of 
processing elements, till the last processing layer, which produces output of the neural network. 
Figure 3. Schematic representation of feed-forward neural network. 
 
ANN is defined by the following parameters: (1) interconnection pattern between different layers of 
neurons; (2) the learning process for updating the weights of the interconnections; and (3) activation 
function that convert a neurons input to its output activation. Activation functions that are used in 
ANNs are sigmoidal, piecewise linear, step, Gaussian, exponential, logistic sigmoidal, etc. [3]. 
Training of the network is in fact the “learning process”. It could be divided into:  
(1) supervised learning: when network weights are adjusted using the known data, split into  
input-output pairs. Supervised learning is the most commonly used training method for ANNs 
and will be further explained in this paper; 
(2) unsupervised learning: it refers to the problem of trying to find hidden structure in unlabeled 
data. Since the examples given to the learner are unlabeled, there is no error or reward signal to 
evaluate a potential solution;  
(3) reinforcement learning: which differs from standard supervised learning in that correct 
input/output pairs are never presented.  
Training of an ANN is actually adjustment of weight values in order to obtain the best nonlinear 
relationship between parameters used as inputs and outputs of the network. At the beginning of the 
training process, weights between the neurons have random values. During the training phase 
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input/output data pairs are presented to the network, and the network searches for the input-output 
relationships. One cycle of input-output presentation to the network is called an iteration (epoch). 
Process of the network training can be thought of as search for the optimal weights values that 
successfully convert inputs to outputs through sometimes numerous iterations. This process is often 
called convergence [5]. During the process of the weights adjustment (i.e., network training), some of 
the interconnections are strengthened and some are weakened, so that a neural network will output a 
more correct answer [4]. Once the optimal set of weight values is found, the network training stops and 
squared error between the actual (training) output values and the ones predicted by the network is 
minimal at this point. At the beginning of the training process, data is divided in two subsets: training 
and test. Training data is used to search for the optimal weight values, whereas by using test data the 
network checks its predictive ability internally. The sum of squared errors (SSE) for the training and 
test subsets can be calculated using the following equation [6]:  
 2
1 1
1 N M
pi pi
p i
SSE t o
N  
 
 
(2) 
where opi is the output predicted by the network of ith output node from pth sample; tpi is the training 
(actual) output of the ith output node from pth sample; N is the number of the training samples and M 
is the number of the output nodes.  
In the process of the network training, the progress of change of error for both training and test data 
sets are evaluated simultaneously. In the case of training data set, SSE decreases indefinitely with 
increasing number of hidden nodes or training iterations (epochs) [5]. Initially, SSE for the training set 
decreases rapidly due to learning, whereas its subsequent slower decrease is attributed to memorization 
or overfitting (if the number of training cycles or hidden nodes is too large). In the case of test data set, 
SSE decreases initially but subsequently increases due to memorization and overfitting of the ANN 
model [5]. It is therefore recommended to stop the training once the test error starts to increase and to 
select the number of hidden nodes when the test error is minimal [5]. Steps in the supervised network 
training and usage are presented in Table 1. 
Table 1. Steps in the supervised network training and usage. 
Training of the network 
 Data is presented to the network 
 Network computes an output 
 Network output is compared to desired output 
 Network weights are modified to reduce error 
Usage of the network 
 Present new, unseen data to the network 
 Network computes an output based on its training 
It is important to emphasize that ANNs work as “black boxes”. It is not possible to see the 
mathematical relationship between inputs and the output.  
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2.2. Basic Topologies (Architectures) of Artificial Neural Networks 
Generally, ANNs could be divided into static ANNs and dynamic ANNs. Differences between 
static and dynamic networks are in the way in which signals are transmitted through the network. 
In order to obtain relevant and reliable results by using ANN models, it is recommended that the 
number of experimental runs is 10 times greater in comparison to the number of inputs; or, if this is not 
feasible, at least two to three times the number of inputs [5]. It is, therefore, practical to first conduct 
screening experimental design, in order to select the most significant input variables that influence 
output properties since it leads to reduction of the number of the ANN inputs (and number of the 
examples needed for the network training at the same time).  
2.2.1. Static Networks 
There are numerous types of static neural networks. The most frequently used static neural network 
in pharmaceutical development is the multilayer perceptron network. 
Multilayer perceptron (MLP) is the simplest neural network architecture, that is a feedforward 
artificial neural network model that maps sets of input data onto a set of appropriate outputs. An MLP 
consists of multiple layers of nodes in a directed graph, with each layer fully connected to the next one 
(Figure 4). Except for the input neurons, each neuron has a nonlinear activation function. MLP utilizes 
a supervised learning technique called the backpropagation algorithm [7,8]. For an MLP neural 
network, the relationship between the inputs and outputs can be represented as follows: 
1 1 0
o h iN N N
i o o ho h h ih i
o h i
y f b w f b w x
  
             (3)
where xi and yi are networks primary input and output; wih and who (i = 1, 2, …, Ni; o = 1, 2, …, No) are 
the weights of the connections between the input and hidden units, and between the hidden and the 
output units, respectively. bh and bo are biases of hidden units and output units, and fh(·) and fo(·) are 
hidden and output functions respectively [9]. Biases are neurons that always have constant values and 
serve to allow certain shifting in the predicted outputs (i.e., they can be thought of as function intercepts).  
Figure 4. Example of Multilayer perceptron (MLP) network architecture with four layers 
(first layer with four neurons, second and third layers with three neurons and fourth layer 
with one neuron). 
 
Generalized regression neural network (GRNN) was first introduced by Specht [10]. It models the 
function directly from the data. It was recognized that GRNNs have been derived from statistical 
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method of function approximation [11]. GRNNs always have exactly four layers: input layer, a layer of 
so-called radial centers, a layer of regression units and output layer (Figure 5).  
Figure 5. Example of generalized regression neural network (GRNN) architecture. 
 
Radial layer is used to perform clustering on the known, training data. Clustering algorithms usually 
used for training of this layer are sub-sampling, K-means or Kohonen [12]. The number of clusters, 
i.e., radial units (neurons) can be optimized and usually it corresponds to the number of the training 
samples. Regression layer has one unit (neuron) more than the output layer and their activation 
function is linear. One extra unit (in comparison to the output layer) is used for calculation of the 
probability density whereas remaining units are used for calculation of outputs. In the output layer a 
specialized function is applied where the calculated outputs of the regression layer are divided by the 
probability density [12]. 
Fundamental equation of GRNN can be presented as:  
1
1
exp( ( , ))
exp( ( , ))
n
i i
i
n
i
i
y D x x
y
D x x








 (4)
where the distance D between the training sample and the point of prediction, is used as a measure of 
how well the each training sample can represents the position of prediction, using the standard 
deviation or the smoothness parameter, σ [10].  
2
,
1
( , )
p
j j i
i
j j
x x
D x x 
       (5)
The advantage of the GRNN is that its training is much faster compared to MLPs. 
2.2.2. Dynamic Neural Networks 
Dynamic (or recurrent) networks have the ability to store data and elaborate it in time. That is the 
advantage of dynamic neural networks (compared to the static networks). Every input is analyzed as a 
function of the previous input. The network remembers past inputs; therefore, the current output is 
integration of past inputs and current response of the system [13]. 
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Connections between the neurons can be set up to have a memory which is very important for 
dynamic networks. The order of the memory says how many time steps the signal will be delayed. 
Treatment of dynamic data requires this kind of temporal dependencies of signal channeling. Network 
topology (architecture), together with the control system for time delay of the signal, forms a complete 
system. Correction of weights in the dynamic neural network is somewhat more complicated, in 
comparison to static neural networks. It is possible to use the technique called backpropagation 
through time where the backpropagated signal is buffered and reversed which enables getting forward 
and backpropagated signals synchronized in time [13].  
Gamma memory is a specific short memory recurrent structure which preserves temporal 
information about the system. Distinctive feature of gamma memory is the number of taps-number of 
signal delays. For a given number of taps memory remembers previous system states and integrates 
them with current ones. From the point of view of signal transmittance Gamma memory can be seen as 
recursive low-pass filter (each output gives a more filtered version of the original signal) which acts as 
an infinite response filter. It is ideal for adaptive systems since its interpolation weight μ can be 
adapted using the usual algorithms. An important class of memory filters is based on the  
(non-dispersive) delay operator. Gamma memory is actually a combination of Tapped-Delay-Line 
(TDL) and a simple feedback neuron. So, the signals gk(t) at the taps k in time t of the Gamma memory 
are convulsions of the impulse response gk tap k [13]. 
A K-th order tapped delay line, the memory structure for Time Delay Neural Network  
(TDNN) [14], can be regarded as a single-input-K-output filter with impulse responses gk(t) = d(t − k).  
Depending on the way that signals are sent back in the neural network, partial or full recurrence 
exists. Partial recurrence occurs, for example, when recurrent connections are sent from the hidden 
layer back to itself. In the fully recurrent networks the final output (of the network) is sent back into 
the network. If connections between the neurons are set up to have a memory then the order of the 
memory says how many time steps the signal will be delayed (default value is one time step, i.e., −1). 
Over time, the network stores long term memory structure in its feedback (recurrent) and regular 
connections, whose weights are adjusted during the training [15]. 
Elman neural network (ENN) is considered as a special kind of feed-forward networks that has 
additional memory neurons and local feedback [16]; therefore it is a simple dynamic neural network. 
Recurrent links are used to provide network with a dynamic memory when hidden unit patterns are fed 
back to themselves [17]. Activation functions of neurons in the hidden layer are fed back to copied 
layer at every time step to provide an additional input in conjunction with other input features. This 
recurrence gives the network dynamic properties, which make it possible for the network to have 
internal memory [18].  
Essential characteristic of Elman neural network (Figure 6) is the fact that a copied (context) layer 
exists that serves as the temporary memory of the hidden layer outputs. Once the signal is transferred 
from the input layer to the hidden layer, it is elaborated and sent both to output and copied layer. 
During the first input–output cycle, copied layer is empty, i.e., its outputs are equal to 0. Then, when 
the activation function in the hidden layer is applied for the first time its outcomes are sent to output 
and copied layer. During the second training cycle, the hidden layer receives inputs from both input 
and copied layer which are then combined and analyzed simultaneously. The process is repeated for 
the next training cycles so that each time the copied layer contains values of the outputs of hidden 
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layer from the previous training cycle. This type of signal recurrence is recognized as a one-step time 
delay [9]. The algorithm of ENN can be represented as follows: 
1 1 0 0
( ( 1))
o h i hN N N N
k o o ho h h ih i jh h
o h i j
y f b w f b w x w a k
   
             (6)
where xk and yk are networks primary input and output; wih, wjh and who (i = 1, 2, …, Ni; j, h = 1, 2, …, 
Nh; o = 1, 2, …, No) are the weights of the connections between the input and hidden units, between the 
copied and the hidden units and between the hidden and the output units, respectively. bh and bo are 
biases of hidden units and output units, and fh(·) and fo(·) are hidden and output functions respectively. 
The weights of the copied layer determine the impact of signal recurrence on the networks output.  
Figure 6. Topology of Elman neural network. 
 
2.3. Application of ANNs in Formulation and Evaluation of Modified Release Dosage Forms 
A pioneer work in the field was a paper published by Hussein et al. in 1991. They modeled the  
in vitro release characteristics of drugs in matrices prepared from various hydrophilic  
polymers [19,20]. Neural networks with a single hidden layer were applied to predict drug release  
from matrix tablets. Predicted drug release profiles were comparable with those generated through  
the use of statistical analysis [19]. 
Chen and coworkers [21] studied the influence of seven formulation variables and three tablet 
variables (moisture, particle size and hardness) on dissolution-time profiles at ten sampling times. 
Twenty two formulations were used for the network training. The optimized ANN model was 
constructed by selecting the optimal number of hidden layers and neuron number in each layer. 
Optimized ANN model was used for prediction of formulations based on two desired target dissolution 
profiles, as well as two desired bioavailability profiles. 
In modeling of a roller-compaction process, Turkoglu et al. [22] varied four formulation and 
process variables through 42 experiments. Results were analyzed using ANN with genetic algorithms. 
When a set of validation experiments was analyzed, genetic algorithm predictions of tablet 
characteristics were much better than the ANN.  
Optimization of theophylline release from controlled release tablets was performed according to 
desirable drug release profiles, based on the plasma concentration profiles of theophylline predicted by 
the pharmacokinetic analysis in humans [23]. Experimentally observed drug release profiles from  
16 formulations were used for ANN training. Simultaneous optimization was performed by 
minimizing the generalized distance between the predicted values of each response and the desirable 
one that was optimized individually. Similar study was performed by Peh et al. [24] with optimization 
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of glyceryl monostearate matrix tablets. MLP neural network was trained and the closeness between 
the predicted and the reference dissolution profiles was investigated using similarity factor (f2). 
In a number of papers, ability of ANNs to predict controlled release profiles of a drug was 
compared with the response surface methodology [25,26]. In general, formulations were optimized 
using both RSM and ANNs. Afterwards, predicted profiles were compared with experimentally 
observed. Differences between predicted and experimentally observed results were discussed.  
Generalized regression neural network was applied in optimization of formulation of aspirin matrix 
tablets with Eudragit RS and Eudragit L, as matrix forming materials [12,27]. The percent of Eudragit 
and tablet hardness were inputs of the network, varied according to the central composite design, while 
percent of aspirin released at 4 sampling time points, as well as release exponent of Korsmayer–Peppas 
equation were outputs of the network. In another study, the same authors applied GRNN network in 
predicting drug stability in matrix tablets [28]. Optimization of formulation with respect to drug release 
profile, as well prediction of drug stability showed abilities of GRNN network in formulation of 
controlled release preparations. It seems that this type of network has ability to optimize controlled 
release formulations better then MLP network. Also, training with GRNN network is much faster than 
with other network types [12].  
Dynamic neural networks were for the first time applied in the prediction of drug release profiles 
from controlled release formulation in 2002 [18]. Drug release profiles were treated as time series 
curves in which information contained in one time point affects further predictions. Elman recurrent 
network was applied. Since in dynamic neural networks data is stored and elaborated in time, it is 
expected that it could be useful in time dependent processes, like drug release prediction or drug 
stability issues. Therefore, our research group have successfully applied dynamic neural networks in 
establishing design space for formulation of matrix tablets and compared those results with static 
networks [13,29,30]. Following case study presents our unpublished data and could be useful for the 
readers as a guide in selection and development of appropriate network for the problem studied. The 
aim of the study was to develop an ANN model for optimization of matrix tablets mechanical 
properties and drug release profile as well. Inputs were ratio of matrix forming material (Polyox WSR 
1105 and Polyox WSR Coagulant) and compression force, while mechanical properties (porosity and 
the tensile strength) of tablets, as well as drug release profiles were outputs of the network (Figure 7).  
Figure 7. Schematic representation of inputs and outputs for the optimization of matrix tablets [30]. 
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Eleven formulations were prepared (nine, according to full 32 factorial design for network training 
and two for network testing). Network topology was chosen according to the flow diagram presented 
in Figure 8.  
Figure 8. Flow diagram for the network architecture selection [30]. 
 
Firstly, MLP network was chosen, as the most frequently used static neural network. The structure 
of MLP network used in the study is presented in Figure 9.  
Figure 9. Schematic representation of MLP network. 
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When the trained MLP network was tested using the test formulations with respect to mechanical 
properties, the model developed by MLP network enables prediction of porosity and tensile strength 
for test formulation, on the basis of known compression force and weight ratio of PEO polymer used 
(Table 2).  
Table 2. Observed versus MLP predicted values for test formulations. 
Formulation Observed values Porosity (%) 
and tensile strength (MPa) 
Predicted values Porosity (%) and 
tensile strength (MPa) (r2 = 0.9982) 
Test 1 19.55 ± 0.49 
1.304 ± 0.042 
20.34 ± 0.78 
1.313 ± 0.155 
Test 2 17.55 ± 0.55 
1.661 ± 0.035 
17.33 ± 0.78 
1.539 ± 0.155 
Afterwards, the same MLP network was used for training, when the outputs were drug release 
profiles. Percents of drug released in predetermined time intervals were outputs of the network. Inputs 
of the network were the same as in previous case. After the training session, the established network 
was not able to predict drug release profiles for test formulations. The calculated values for similarity 
factor indicated that profiles are not similar (f2 55.37 and 48.22 for test 1 and test 2 formulation, 
respectively). The next step was to change the network type and to evaluate the drug release prediction 
using dynamic neural networks. Gamma memory one layer dynamic neural network was applied 
(GMDNN) (Figure 10). Gamma memory (GM) used had 4 taps.  
Figure 10. Schematic representation of gamma memory dynamic neural network (GMDNN). 
 
From GM signal is transferred to the first function layer, then to the weight layer and subsequently 
to the second function layer. Delta terminator compares two signals: one comes from the data source 
and represents real, observed outputs; whereas the second signal comes from the second function layer 
and represents outputs predicted by the dynamic system. The number of inputs and outputs in weight 
and function layers, as well as tapped delay line, were optimized using Monte Carlo simulations. As in 
the case of model developed by MLP, the obtained model does not predict drug release successfully. 
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GM predicted shifting of profiles towards higher percentage of drug released after second hour of 
study, which was not confirmed experimentally. Topology of the recurrent one layer dynamic neural 
network (OLDNN), which was next used in the training, is presented in Figure 11.  
Figure 11. Representation of recurrent one layer dynamic neural network (OLDNN): 
(a) Peltarion® software layout and (b) network’s schematic representation. 
(a) 
 
Most of the networks elements were the same as in previously described GMDNN. From the first 
data source inputs are transferred to the first weight layer. The first weight layer has 2 inputs and  
17 outputs. The number of its outputs was optimized using Monte Carlo simulations. OLDNN is a 
partially recurrent network since the recurrent connections are sent from the hidden layer back to itself 
(first function layer). In the fully recurrent networks the output is sent back into the network. From the 
first, recurrent function layer, signal goes to the second weight layer that has 17 inputs and 10 outputs. 
Then the signal goes to the second functional layer, which is an ordinary function layer. Once again, 
the network was trained and afterwards tested. The model obtained using OLDNN enabled adequate 
prediction of drug release profiles, with similarity factors for test formulations 64.01 and 77.54, 
respectively. Even though results obtained using this network were better, there were still shifting 
values of predicted drug release profiles compared to experimentally observed values at later time 
points. Therefore, in the next study [29], the starting point of experiments was changed: since it was 
demonstrated that mechanical properties of the tablets have impact on drug release, porosity and the 
tensile strengths were selected to be inputs, together with ratio of the polymer and compression force. 
Elman dynamic neural network was applied, with topology shown in Figure 12. This type of network 
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was also applied in modeling of drug release from lipid matrix tablets [29]. After the training session, 
prediction of drug release from test formulations was better in comparison to OLDNN application.  
Figure 12. Representation of Elman dynamic neural network. 
 
In Table 3, studies on formulation, characterization and optimization of modified release 
formulations are listed, with respect to inputs/outputs selected, type of the network used, and the 
authors and year of performed studies. 
Table 3. Formulation, characterization and optimization of modified release solid dosage 
forms are listed, with respect to inputs/outputs selected, type of the network used, and the 
authors(year) of performed studies. 
Formulation, characterization and optimization of modified release formulation 
Inputs/outputs/aim Network type Authors, year 
Design of controlled release formulations. Varying formulation 
variables were used as inputs and in vitro cumulative 
percentages of drug released were used as ANN outputs. 
MLP Chen, 1999 [21] 
Optimization of diclofenac sodium sustained release matrix 
tablets. Trained model was used to predict release profiles and to 
optimize the formulation composition. 
MLP Zupancic Bozic, 
1997 [31] 
Design of extended release aspirin tablets. The amount of 
Eudragit® RS PO/Eudragit® L-polymer and compression 
pressure were selected as inputs, whereas in vitro dissolution 
profiles, release order and release constant from the Korsmayer 
Peppas equation were selected as output parameters. 
GRNN Ibric, 2002, 2003, 
2007 [12,27,28] 
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Table 3. Cont. 
Formulation, characterization and optimization of modified release formulation 
Inputs/outputs/aim Network type Authors, year 
Prediction of drug dissolution profiles. Inputs for the network 
training were the matrix forming agents’ ratio, the time point of 
the measurement of percent dissolved, and the difference 
between the release rate of the preceding two time points of the 
predicted profile. In vitro dissolution profiles were used as 
network outputs. 
MLP Peh, 2000 [24] 
Investigation of controlled drug release. Drug fraction and  
time were used as network inputs and in vitro dissolution 
profiles as outputs. 
MLP Reis, 2004 [32] 
Prediction of dissolution profiles for matrix controlled release 
theophylline pellet preparation. Inputs for the network training 
were the matrix forming agents’ ratio, and the time point of the 
measurement of percent dissolved; in vitro dissolution profiles 
were used as outputs. 
EDNN Goh, 2002 [18] 
Modeling of diclofenac sodium release from Carbopol 71G 
matrix tablets. Polymer and binder content were inputs, while  
in vitro dissolution profiles were outputs 
MLP Ivic, 2010a [26] 
Modeling of diclofenac sodium release from polyethylene oxide 
matrix tablets. Polymer weight ratio and compression force were 
used as inputs, whereas in vitro dissolution profiles were used as 
networks outputs. Dissolution profiles were treated as time series 
using dynamic neural networks. 
MLP, 
GMDNN, 
OLDNN 
Petrović, 2009 [13] 
Drug release control and system understanding of sucrose esters 
matrix tablets. Networks inputs were HLB values of sucrose 
esters (SEs), SEs concentration, tablet volume, tablet porosity 
and tablet tensile strength. In vitro dissolution profiles and 
parameters indicative of burst release mean dissolution time and 
release exponent were used as outputs.  
MLP Chansanroj, 2011 
[33] 
A number of unique ANN configurations are presented, that 
have been evaluated for their ability to determine an IVIVC 
from different formulations of the same product. In vitro 
dissolution data were used as inputs and associated outputs were 
pharmacokinetic time points from nine patients enrolled in a 
crossover study.  
MLP, GRNN, 
RNN Dowell, 1999 [34] 
Development of level A in vitro–in vivo correlation.  
Inputs for the network training were in vitro dissolution  
samples whereas in vivo dissolution profiles calculated by 
numerical deconvolution for each volunteer individually were 
used as outputs. 
GRNN Parojčić, 2007 [35] 
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Table 3. Cont. 
Formulation, characterization and optimization of modified release formulation 
Inputs/outputs/aim Network type Authors, year 
Prediction of relative lung bioavailability and clinical effect of 
salbutamol when delivered to healthy volunteers and asthmatic 
patients from dry powder inhalers (DPIs). Training of the ANN 
network was performed using in vitro aerodynamic 
characteristics of the formulation and demographic  
data of volunteers/patients as input parameters, whilst in vivo 
data (urinary excretion of the drug and its metabolite) were 
networks outputs.  
MLP De Matas, 2008 [36] 
Prediction of kinetics of doxorubicin release from sulfopropyl 
dextran ion-exchange microspheres. Three independent 
variables, drug loading level, concentration of NaCl and CaCl2 
in the release medium were used as the ANN inputs and the 
fractional release of doxorubicin at four different time points as 
the outputs. 
MLP, 
HNN Li, 2005 [37] 
Prediction of drug release profiles in transdermal iontophoresis. 
Neural networks inputs were the process conditions of pH, ionic 
strength and current, as well as the time point. The output was 
the predicted permeation rate of the drug (diclofenac sodium). 
RBFNN Lim, 2003 [38] 
Optimization of drug release from compressed multi unit  
particle system (MUPS) using generalized regression neural 
network (GRNN) 
GRNN Ivic, 2010b [39] 
Abbreviations: MLP, Multilayered Perceptron; GRNN, Generalized Regression Neural Network;  
RBFNN, Radial Basis Function Neural Network; EDNN, Elman Dynamic Neural Network;  
GMDNN, Gamma memory Dynamic Neural Network; OLDNN, One Layer Dynamic Neural Network;  
HNN, Hierarchical Neural Network.  
The mutual idea of presented studies could be described as follows: they attempted to create a 
relationship between formulation and/or process variables (INPUTS) in production of modified release 
preparation (regardless of whether they were matrix tablets or multiple unit systems) and drug release 
profiles or dissolution rate constants (OUTPUS). In the training session, prediction capability of the 
trained networks was tested comparing predicted and experimentally observed drug release profiles, 
using the similarity factor as parameter and/or correlation coefficient. 
To date, there are many commercial, as well as freely available computer programs that can be used 
for ANN modeling. It should be pointed out that modeling of the same data through different  
software will give a little bit different results. An interesting study has been published by Chen and 
coworkers [40]. They compared four commercially ANN software programs to predict the in vitro 
dissolution profiles of controlled release tablets. The ANNs developed from the four software 
programs were validated by predicting the in vitro dissolution time-profiles of each of the  
19 formulations, which were excluded from the training process. Although the same data set was used, 
the optimum ANN architectures generated from the four software programs was different. 
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Nevertheless, it was concluded that the four programs provided reasonable predictions of in vitro 
dissolution profiles for the data set employed in this study. 
3. Future Prospects 
So far, a lot of work has been done concerning application of ANNs in optimizing drug release 
profiles from controlled release formulation. As neural computing is progressing, current trends and 
recently published articles [29,33,41–43] indicate that the future state in this area will include 
integration of ANNs with other machine learning techniques, such as fuzzy logic, genetic 
programming, decision trees, self-organizing maps, etc. Decision tree methodology, a nonparametric 
statistical technique, used for classification problems, could be successfully used in characterization of 
controlled release problems, as was reported. The main constraint of this methodology is that it 
requires a large data set, because inductive generalization given in the form of a decision tree is 
dependent on a sufficient amount of data [29].  
There have been very few attempts to use genetic programming in the optimization of 
pharmaceutical formulations [42–44]. Published results indicate that symbolic regression via genetic 
programming is a promising technique; in comparison to ANN models, it provides parametric 
equations, which can be more easily interpreted, thus having a greater potential for understanding of 
the mechanisms of the modeled process [43].  
However, ANN models are well established and could be used in implementation of Quality by 
Design concept, i.e., understanding of Design Space and Quality Risk Management for modified 
release formulations.  
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